Novo Nordisk Patents – Insights & Stats

Novo Nordisk has a total of 1395 patents globally, out of which 642 have been granted. Of these 1395 patents, more than 49% patents are active. European Countries is where Novo Nordisk has filed the maximum number of patents, followed by USA and Japan, it has generated an annual revenue of $52.36 billion in the year 2021. Parallelly, USA seems to be the main focused R&D centre.

Novo Nordisk was founded in the year 1923 by August Krogh and Marie Krogh. Headquartered in Bagsvaerd, Denmark, it is a Danish multinational pharmaceutical corporation. It develops, manufactures, and distributes pharmaceutical products and services, with a focus on diabetes drugs and devices. As of April 2022, Novo Nordisk has a market cap of $268.69 Billion.

Do read about some of the most popular patents of Novo Nordisk which have been covered by us in this article and also you can find Novo Nordisk’ patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Novo Nordisk’ patent portfolio.

How many patents does the founder and the CEO of Novo Nordisk have?

The founders, August Krogh and Marie Krogh, have 7 and 0 patents respectively. The CEO, Lars Fruergaard Jørgensen, has 0 patents.

How Many Patents did Novo Nordisk File Every Year?

Novo Nordisk Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantNovo Nordisk Applications FiledNovo Nordisk Patents Granted
20116829
20124144
20134542
20145250
20154831
20161036
20173844
20187232
20197638
20206929
20215644
202214

How many patents does Novo Nordisk have?

Novo Nordisk has a total of 1395 patents globally. These patents belong to 232 unique patent families. Out of 1395 patents, 696 patents are active.

How many Novo Nordisk patents are Alive/Dead?

Worldwide Patents

Novo Nordisk Worldwide Patent Portfolio

How Many Patents did Novo Nordisk File in Different Countries?

Novo Nordisk Worldwide Patent Filing

Countries in which Novo Nordisk Filed Patents

CountryPatents
Europe140
United States Of America121
Japan110
Australia100
Canada85
Germany75
Hong Kong (S.A.R.)66
China62
Israel53
Korea (South)49
Spain48
India41
Brazil38
Mexico37
New Zealand36
Singapore29
South Africa21
Austria21
Denmark20
Russia17
Taiwan14
Portugal13
Chile10
Poland9
Indonesia6
Hungary6
Czech Republic5
Norway5
Argentina4
Malaysia3
Colombia2
Viet Nam2
Lithuania2
Peru2
Cyprus2
Philippines1
Slovakia1
Finland1
Macao1
Slovenia1
Dominican Republic1
Costa Rica1
Ecuador1
Croatia1
Uruguay1
Albania1
Morocco1
Serbia1
Jordan1

Which Novo Nordisk Drug Patents are Expiring in the Next 10 Years?

The patent no. US9968659B2 which is expiring in Jan, 2037, describing use of liraglutide to treat type 2 diabetes in individuals with vascular diseases or risk factors. Administering a therapeutically effective amount to those with cardiovascular, cerebrovascular, or peripheral vascular diseases, chronic renal failure, chronic heart failure, and/or risk factors like microalbuminuria, proteinuria, hypertension, and others..

Given below is the list of few drugs patented by Novo Nordisk accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.

Drug NamePatent NumberPatent TitlePatent Expiration
SaxendaUS9968659B2Liraglutide In Cardiovascular ConditionsJan, 2037
OzempicUS8129343B2Acylated GLP-1 CompoundsDec, 2031
RybelsusUS10278923B2Oral Dosing Of GLP-1 CompoundsMay, 2034
VictozaUS9265893B2Injection ButtonSep, 2032
WegovyUS10888605B2GLP-1 Compositions And Uses ThereofAug, 2038

Where are Research Centres of Novo Nordisk Patents Located?

Research Centres of Novo Nordisk

10 Best Novo Nordisk Patents

US8513207B2 is the most popular patent in the Novo Nordisk portfolio. It has received 173 citations so far from companies like Genentech, Dicerna Pharmaceuticals, and Omega Therapeutics.

Below is the list of 10 most cited patents of Novo Nordisk:

Publication NumberCitation Count
US8513207B2173
WO2013059496A1155
US8349809B2135
WO2002002509A1120
US20020065255A1113
WO2008028859A178
WO2002016309A170
WO2010033225A268
US6610329B267
WO2007121318A266

Which Companies are using Novo Nordisk Patents to Advance their Research?

If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.

The top citing companies in the Novo Nordisk patent portfolio are Arrowhead Pharmaceuticals, Roche Holding, and Novartis.

List of the top forward citing Companies –

CompanyNumber of Patents
Arrowhead Pharmaceuticals10
Roche Holding3
Novartis3
Translate Bio Ma3
Keybioscience3
Nanosur3
Olix Pharmaceuticals2
Alnylam Pharmaceuticals2
Honeywell2
Ionis Pharmaceuticals1

Count of 102 and 103 Type Rejections based on Novo Nordisk Patents

Top Novo Nordisk Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US20020065255A17
US20030198666A16
US20060078622A15
US9458457B25
US20100249214A15
US8815825B24
US20110288147A14
US9701966B24
US20120095200A14
US20170305956A13
US20050203001A13
US8349809B23
US20110059187A13
US20120263738A13
US8513207B22

Type 1 diabetes is a chronic illness in which the body’s capacity to convert glucose from food into energy is impaired. Type 1 diabetes usually develops early in life and is diagnosed during childhood. People with type 1 diabetes would not be able to sustain life if they did not receive daily insulin injections.

Their scientists are advancing research to reduce the number of insulin injections required to maintain good glycaemic control and to prevent low blood glucose (hypoglycaemic) episodes.

The natural GLP-1 hormone is also receiving a lot of interest from the pharmaceutical company. They’re learning more and more about the role that this naturally occurring hormone appears to play in weight loss success. GLP-1 molecules in the body, for example, impact a person’s hunger feelings after they’ve finished a meal.

They’ve been researching how synthetic GLP-1 molecules can be utilised to suppress appetite or raise energy expenditure for numerous years. They’ll also keep looking into how GLP-1 can promote long-term weight loss.

EXCLUSIVE INSIGHTS COMING SOON!

What are Novo Nordisk’s key innovation segments?

What Technologies are Covered by Novo Nordisk?

The chart below distributes patents filed by Novo Nordisk in different countries on the basis of the technology protected in patents. It also represents the markets where Novo Nordisk thinks it’s important to protect particular technology inventions.

R&D Focus: How has Novo Nordisk‘s search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Novo Nordisk?

Related Articles

Hayco Patents – Insights & Stats (Updated 2024)

Hayco has a total of 156 patents globally, out of which 123 have been granted. Of these 156 patents, more than 12% patents are active. United States of America is where Hayco has filed the maximum number of patents, followed by China and Europe (EPO). Parallelly, China seems to be

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.